Home › Funds › Carroll Investors, Inc › RXRX
Carroll Investors, Inc position in RXRX
RECURSION PHARMACEUTICALS IN · Health Care
Carroll Investors, Inc reported holding 502,550 shares of RXRX (RECURSION PHARMACEUTICALS IN) in its Q3 2026 13F filing — a position valued at US$2.1M, representing 0.79% of its reported portfolio and ranking #17 among its reported holdings. Carroll Investors, Inc has disclosed RXRX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Carroll Investors, Inc's RXRX position evolved
Carroll Investors, Inc first disclosed a stake in RXRX in Q1 2024 at 13,799 shares (US$138K). The position peaked in Q3 2026 at 502,550 shares, worth US$2.1M. Across 11 filings, Carroll Investors, Inc increased the stake 8 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 502,550 shares valued at US$2.1M. Notable position changes include a 485% increase in Q2 2024 (shares fell 12% over the following quarter), a 101% increase in Q3 2024 (shares rose 3% over the following quarter), a 52% increase in Q4 2024 (shares fell 22% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 13.80K | $137.58K | New |
| Q2 2024 | 80.77K | $605.75K | Add |
| Q3 2024 | 162.74K | $1.08M | Add |
| Q4 2024 | 246.99K | $1.67M | Add |
| Q1 2025 | 341.33K | $1.81M | Add |
| Q2 2025 | 385.60K | $1.95M | Add |
| Q3 2025 | 396.70K | $1.94M | Add |
| Q4 2025 | 404.94K | $1.66M | Add |
| Q1 2026 | 509.43K | $1.56M | Add |
| Q2 2026 | 500.35K | $1.84M | Reduce |
| Q3 2026 | 502.55K | $2.08M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RXRX and 13F data
RXRX (RECURSION PHARMACEUTICALS IN) is a Health Care company. 29 other funds we track also report a position in RXRX — the largest reported positions include ARK Invest (US$184.8M), SOFTBANK GROUP CORP. (US$50.0M), MIC Capital Management UK LLP (US$35.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RXRX
- ARK Invest 44.75M sh · $184.80M · Q3 2026
- SOFTBANK GROUP CORP. 13.64M sh · $50.05M · Q2 2026
- MIC Capital Management UK LLP 9.64M sh · $35.39M · Q2 2026
- Data Collective IV GP, LLC 5.94M sh · $21.80M · Q2 2026
- DCVC Opportunity Fund II GP, LLC 3.95M sh · $14.50M · Q2 2026
- IQ EQ FUND MANAGEMENT (IRELAND) Ltd 2.68M sh · $11.06M · Q3 2026
More on Carroll Investors, Inc
FAQ
How long has Carroll Investors, Inc held RXRX?
Carroll Investors, Inc has disclosed RXRX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is Carroll Investors, Inc's current position in RXRX?
As of Q3 2026, Carroll Investors, Inc holds 502.55K shares of RXRX (RECURSION PHARMACEUTICALS IN), valued at $2.08M, representing 0.79% of its reported portfolio and ranking #17.
Has Carroll Investors, Inc been buying or selling RXRX?
In the latest 13F filing (Q3 2026), Carroll Investors, Inc held unchanged its position in RXRX. The position peaked in Q3 2026 at 502.55K shares.
Which other funds hold RXRX?
Other major institutional holders of RXRX include ARK Invest, SOFTBANK GROUP CORP., MIC Capital Management UK LLP, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.